ZA200101048B - Method of mitigating the adverse effects of Interleukin-2. - Google Patents
Method of mitigating the adverse effects of Interleukin-2. Download PDFInfo
- Publication number
- ZA200101048B ZA200101048B ZA200101048A ZA200101048A ZA200101048B ZA 200101048 B ZA200101048 B ZA 200101048B ZA 200101048 A ZA200101048 A ZA 200101048A ZA 200101048 A ZA200101048 A ZA 200101048A ZA 200101048 B ZA200101048 B ZA 200101048B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- represents hydrogen
- receptor antagonist
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims description 111
- 102000000588 Interleukin-2 Human genes 0.000 title claims description 111
- 230000002411 adverse Effects 0.000 title claims description 42
- 238000000034 method Methods 0.000 title claims description 35
- 230000000694 effects Effects 0.000 title claims description 26
- 230000000116 mitigating effect Effects 0.000 title claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 126
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 37
- 150000002431 hydrogen Chemical group 0.000 claims description 26
- 230000000144 pharmacologic effect Effects 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000004450 alkenylene group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000001589 carboacyl group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 230000036210 malignancy Effects 0.000 claims description 10
- 125000004419 alkynylene group Chemical group 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 8
- 125000004979 cyclopentylene group Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 230000008728 vascular permeability Effects 0.000 claims description 6
- 208000001953 Hypotension Diseases 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000036543 hypotension Effects 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 102000003835 leukotriene receptors Human genes 0.000 claims description 4
- 108090000146 leukotriene receptors Proteins 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 101100379079 Emericella variicolor andA gene Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- -1 i- propyl Chemical group 0.000 description 13
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 108700025316 aldesleukin Proteins 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229940087463 proleukin Drugs 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 210000002751 lymph Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000002617 leukotrienes Chemical class 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000002612 cardiopulmonary effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZVVCSBSDFGYRCB-UHFFFAOYSA-N 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(O2)C(O)=O)C2=C1CCC ZVVCSBSDFGYRCB-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 241001227713 Chiron Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 3
- 229960003974 diethylcarbamazine Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- HMXJOWDZAJWLTF-UHFFFAOYSA-N 2h-chromene-2-carboxylic acid Chemical compound C1=CC=C2C=CC(C(=O)O)OC2=C1 HMXJOWDZAJWLTF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 2
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 150000001562 benzopyrans Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- SJWFXCIHNDVPSH-MRVPVSSYSA-N (2R)-octan-2-ol Chemical compound CCCCCC[C@@H](C)O SJWFXCIHNDVPSH-MRVPVSSYSA-N 0.000 description 1
- SJWFXCIHNDVPSH-QMMMGPOBSA-N (2S)-octan-2-ol Chemical compound CCCCCC[C@H](C)O SJWFXCIHNDVPSH-QMMMGPOBSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ACUSXPATSKBGLL-UHFFFAOYSA-N 3-[7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-2-methyl-8-propyl-3,4-dihydrochromen-2-yl]propanoic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(C)(CCC(O)=O)O2)C2=C1CCC ACUSXPATSKBGLL-UHFFFAOYSA-N 0.000 description 1
- UKABKULZHUONDI-UHFFFAOYSA-N 3-[7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromen-2-yl]propanoic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(CCC(O)=O)O2)C2=C1CCC UKABKULZHUONDI-UHFFFAOYSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- PUXUTOKJINJKEO-UHFFFAOYSA-N 7-[3-[4-acetyl-2-(cyclopropylmethyl)-3-methoxyphenoxy]propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC=2CCC(C(O)=O)OC=2C(CCC)=C1OCCCOC1=CC=C(C(C)=O)C(OC)=C1CC1CC1 PUXUTOKJINJKEO-UHFFFAOYSA-N 0.000 description 1
- ZZDPYZNCUJUHRZ-UHFFFAOYSA-N 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-6-benzoyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCCCOC(C(=C1)C(=O)C=2C=CC=CC=2)=CC2=C1CCC(C(O)=O)O2 ZZDPYZNCUJUHRZ-UHFFFAOYSA-N 0.000 description 1
- NLLQQGKLBYXZPE-UHFFFAOYSA-N 7-[5-(4-acetyl-3-methoxy-2-propylphenoxy)pentoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCCCOC1=CC=C(CCC(O2)C(O)=O)C2=C1CCC NLLQQGKLBYXZPE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
- 101100455054 Homo sapiens LTA4H gene Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100075025 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) LTA4 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- FGGYJWZYDAROFF-UHFFFAOYSA-N ablukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCCCOC(C(=C1)C(C)=O)=CC2=C1CCC(C(O)=O)O2 FGGYJWZYDAROFF-UHFFFAOYSA-N 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026802 afebrile Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003664 filaricide agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 1
- 239000003913 leukotriene B4 receptor antagonist Substances 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- PYDHPHFBIATEMH-UHFFFAOYSA-N methyl 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylate Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCOC1=CC=C(CCC(O2)C(=O)OC)C2=C1CCC PYDHPHFBIATEMH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Description
- ¥ WO 00/12086 PCT/US99/19062 - METHOD OF MITIGATING THE
ADVERSE EFFECTS OF INTERLEUKIN-2
This is a continuation-in-part of USSN 60/098,341, filed August 28, 1998.
INTRODUCTION
This invention relates to mitigating adverse effects induced by interleukin-2 through the administration of an effective amount of a leukotriene receptor antagonist.
Recombinant interleukin-2 (PROLEUKIN® or “IL-2”) is an analogue of human native interleukin-2. While human native interleukin-2 is present in a human in small amounts, under certain conditions, i.e., the administration of IL-2 to treat certain conditions, excess levels (i.e., higher than normal levels) of IL-2 will be present in a ? subject’s system. IL-2 is approved for the treatment of certain human malignancies including melanoma and renal cell carcinoma and is useful in treating certain viral , Cee en FN conditions. The administration of IL-2 has been associated with “vascular leak syndrome” (VLS), which results from extravasation of plasma proteins and fluid into the extravascular space. It is known that, among other adverse signs or symptoms, VLS can cause generalized edema, systemic hypotension, reduced organ perfusion, and subsequent - dysfunction of one or more organs. When sufficiently severe, VLS may cause significant disability or even death. The adverse effects of IL-2 may necessitate using a lower dose of IL-2, thereby diminishing the potential for therapeutic benefit from IL-2. An effective means of mitigating IL-2 toxicity would be beneficial.
Empirical approaches to treating VLS have included the use of corticosteroids, which, unfortunately, can reduce the antitumor effects of IL-2. The pluripotent filaricide diethylcarbamazine (DEC) has also been studied experimentally, but because of its diverse pharmacological effects, the role of DEC in VLS is unclear. The antifolate - methotrexate has also been suggested as a means of mitigating VLS. Unfortunately, methotrexate itself is quite toxic.
As the variety of potential interventions suggests, the pathogenesis of VLS is unknown. It has been demonstrated, however, that IL-2 increases plasma levels of leukotrienes, including leukotriene B4. It is also known that leukotrienes may unfavorably alter vascular permeability. Therefore, blocking leukotriene effects with a leukotriene antagonist (LA) during IL-2 therapy may mitigate VLS and lessen the adverse effects of IL-2.
Relevant Literature 1. Vetto J.T., et al. Reduction of Toxicity of Interleukin-2 and Lymphokine-
Activated Killer Cells in Humans by the Administration of Corticosteroids. J. Clin Oncol 1987,5:496-503 2. Klausner JM., et al. Interleukin-2-Induced Lung Permeability is
Mediated by Leukotriene B4. Cancer 1990;66:2357-64. . 3. Spiro R.C,, et al. Inhibition of post-translational modification and surface expression of a melanoma-associated chondroitin sulfate proteoglycan by diethylcarbamazine or ammonium chloride. J. Biol. Chem. 1986;261:5121-9. 4. U.S. Patent No. 5,593,671. 5. U.S. Patent No. 4,889,871. 6. Staub N.D. et al. Preparation of chronic lung lymph fistula in sheep. J
Surg Res 1975;19:315-20. 7. Edwards, M.J.,, et al. Interleukin Acutely Reduces Platelet and
Neutrophil-Endothelial Adherence and Macromolecular Leakage, Cancer Research 52: 1992 3425-31.
Objects of the Invention a WO 00/12086 PCT/US99/19062 » An object of this invention is to mitigate IL-2-associated adverse signs or symptoms, particularly those associated with VLS.
Another object of this invention is to reduce diagnostic testing required to monitor patient responses to IL-2 and to determine the success of therapeutic interventions required to mitigate IL-2-related adverse events.
Still another object of this invention is to reduce diagnostic testing needed to demonstrate that certain events are caused by IL-2 rather than by another agent, ” Still another object is to reduce the costs associated with treating IL-2-induced adverse events, particularly those associated with VLS. . } 10 Other objects and advantages of the invention may be apparent to one of skill in the art upon reading the following specification and claims.
’ One aspect of this invention is a method of mitigating an adverse pharmacological ? effect of IL-2 in a subject. The method comprises administering to a subject receiving . 15 - exogenous IL-2 an amount of a leukotriene receptor antagonist that is sufficient to mitigate the adverse effects. Another aspect is treating a malignancy or viral infection in a mammal by administering a therapeutically effective amount of IL-2 in combination with a leukotriene receptor antagonist in an amount sufficient to reduce IL-2 — induced adverse pharmacological effects, e.g., increased vascular permeability. _
The preferred leukotriene receptor antagonist is represented by the Formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein ty ) oF i ( \ re °C : RS RS
Cl Nf? o—w —0" |; | 4 RS
NN
H
R!' represents alkyl having 2 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, or (CH;),R wherein R represents cycloalkyl of 3to § carbon atoms and nis 1 or 2;
R? represents hydrogen, methyl or ethyl;
R’ represents alkyl having 1 to 5 carbon atoms;
W represents a bridging group such as (CH,)x where x is 2 to 7, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms or cyclopentyl,
R* represents hydrogen, alkyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkanoyl of 2 to 5 carbon atoms, or aralkanoyl of 7 to 9 carbon atoms;
R® represents hydrogen, alkyl having 1 to 6 carbon atoms, or R® represents alkanoyl having 2 to 4 carbon atoms, or (CHy)y - CO,R® wherein y is 0 to 4 and Ris hydrogen or alkyl having 1 to 6 carbon atoms;
R® represents hydrogen or together with R’ represents a carbon to carbon bond; and ’
A represents - Z - CO,R’ wherein R’ represents hydrogen or alkyl having 1 to 6 carbon atoms, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms.
Other leukotriene receptor antagonists include those set forth in U.S.
Patent 4,788,214 and are incorporated herein by reference.
Another aspect of the invention may be viewed as an improvement in a method of treatment. In a method of treating a malignancy or viral infection in a mammal, which method comprises administering a therapeutically effective amount of IL-2, which 75 administration also induces adverse pharmacological effects in the mammal, the fl : WO 00/12086 PCT/US99/19062 @ iY r : g improvement comprises administering a leukotriene receptor antagonist in an amount sufficient to mitigate IL-2 induced adverse pharmacological effects.
Another aspect of this invention is a process for preparing a pharmaceutical composition. The process comprises combining a leukotriene receptor antagonist with a pharmaceutical excipient to form a composition useful for mitigating IL-2 induced, adverse pharmacological effects in a subject receiving exogenous IL-2.
Still another aspect of this invention is an article of manufacture that comprises a pharmaceutical composition comprising a leukotriene receptor antagonist as a unit dosage in combination with printed labeling instructions for administering the composition to a
B 10 mammal undergoing treatment of a malignancy or viral infection with IL-2, wherein the amount of the composition administered is sufficient to mitigate IL-2 induced adverse pharmacological effects in the mammal being treated.
Figure 1: This figure presents comparative in vivo results showing the effects of a - 15 compound useful in this invention on the reduction of oxygention of arterial blood by IL- ‘2 administration.
For purposes of this application the following definitions apply:
Alkyl means a fully saturated hydrocarbon radical having the number of carbon atoms indicated. For example, alkyl of 1 to 6 includes, e.g., methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, t-butyl, n-pentyl, amyl, n-hexyl, and the like.
Alkenyl means a radical derived from an alkene, i.e., hydrocarbon having a single double bond and having the number of carbons indicated. For example, alkenyl of 2-6 carbon atoms includes radicals derived from ethylene, propylene, 1-butene, 2-butene, isobutylene, 3, 3- dimethylpropylene, and the like.
Alkynyl means a radical derived from an alkyne, i.e., hydrocarbon having a single - triple bond and having the number of carbons indicated. For example alkynyl of 1-6 carbon atoms includes acetylenyl, propynyl, 1-butynyl, 1 pentynyl, 1-hexynyl and the like.
Alkanoyl means a radical represented by the formula RC(O)- where R is alkyl of the number of carbons indicated.
Aralkanoyl means a radical represented by the formula ArC(O) — where Ar is an aryl group of the number of carbons indicated, e.g., phenyl (6 carbons).
LA is the abbreviation for leukotriene receptor antagonist.
Pharmaceutically-acceptable salts are those that are physiologically acceptable for pharmaceutical purposes and include, e.g., ammonium, potassium, sodium, alkaline earth, and the like.
A stereoisomer is one of a set of isomers whose molecules have the same atoms bonded to each other but differ in the way these atoms are arranged in space. Included in this are enantiomers, i.c., compounds that are mirror images of each other but that are not ’ superimposable upon each other.
Compounds Useful in the Invention
While the LA useful in this invention may be any compound that antagonizes (i.e., blocks) a leukotriene receptor, preferably the compound is one that blocks the effects mediated by the leukotriene B4 receptor. A preferred class of compounds is represented by Formula (I) as set forth in the “Summary of the Invention” section of this application or a pharmaceutically acceptable salt thereof. In Formula (I),
R! represents hydrogen, alkyl having 1 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, or (CHz),R wherein R represents cycloalkyl of 3 to 5 carbon atoms and nis 1 or 2;
R? represents hydrogen, methyl or ethyl;
4 WO 00/12086 PCT/US99/19062 ¢ R? represents alkyl having 1 to 5 carbon atoms; : W represents (CH), where x is 2 to 7, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms or cyclopentylene;
R* represents hydrogen, alkyl having 2 to 5 carbon atoms, alkynyl having 2t0 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkanoyl of 2 to 5 carbon atoms or aralkanoyl;
R® represents hydrogen, alkyl having 1 to 6 carbon atoms, or R> represents ” alkanoyl having 2 to 4 carbon atoms, or (CHy)y - CO,R® wherein v is 0 to 4 and R® is : : hydrogen or alkyl having 1 to 6 carbon atoms; : 10 + R® represents hydrogen or together with R’ represents a carbon to carbon bond; : and ” A represents - Z - CO,R” wherein R’ represents hydrogen or alkyl having 1 to 6 # carbon atoms, and wherein Z is absent or represents straight or branched chain alkylene oe or alkenylene having up to 6 carbon atoms. h 15 A preferred subgroup is represented by Formula (I) wherein R! represents alkyl ¢ having 2-4 carbon atoms; R? represents hydrogen, methyl or ethyl; R’ represents alkyl having 1 to 3 carbon atoms; W represents (CHy)x where x is 3 to 5, alkenylene having 3 to 5 carbon atoms, alkynylene having 3 to 5 carbon atoms, or cyclopentylene; R* represents alkyl having 2 to 4 carbon atoms, acetyl or benzoyl; R’ represents hydrogen, or alkyl having 1 to 4 carbon atoms; and A represents - Z - COR’, wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms, and wherein Z is absent or represents alkylene having up to 2 carbon atoms; or a stereoisomer or pharmaceutically acceptable salt thereof | of this subgroup. Particularly useful are compounds represented by
Formula (I) wherein R'is n-propyl; R? and R? each is methyl; W is (CHy)x, Where x is 3,4 or5; R? is n-propyl; R® represents hydrogen or alkyl of 1 to 4 carbon atoms; and A represents - Z - CO,R” wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms and Z is absent or represents alkylene having up to 2 carbon atoms; or a stereoisomer or a pharmaceutically acceptable salt thereof. Particularly preferred is a leukotriene receptor antagonist as represented by Formula (I) wherein R' is n-propyl, R? : and R® each is methyl, R* is n-propyl at the 8 - position. W is (CHy)s; R® is H; and A is (CH,), - COOH, where p is 0,1 or 2, especially 0 or a stereoisomer or a pharmaceutically acceptable salt thereof.
Other compounds useful in this invention are set forth in U.S. Patent 4,788,214.
The compounds represented by Formula (I) in which position 2 of the benzopyran ring is a chiral center exist in racemic form as a mixture of individual enantiomers (i.e., racemate), or as the pure individual enantiomers. Formula (I) is intended to cover the racemic mixture containing equal quantities of dextrorotatory (+) and levorotatory (-) enantiomers as well as the individual dextroratory enantiomer, the levorotatory enantiomer and other non-equal mixtures of enantiomers. The formula is to be interpreted as covering any stereoisomer of the compound.
Representative compounds include the following (or the corresponding pharmaceutically acceptable salts thereof or the stereoisomers): 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1- ; benzopyran-2-carboxylic acid; 7-[[5-(4-acetyl-3-methoxy-2-propylphenoxy)pentyl]oxy]-3,4-dihydro-8-propyl- ) 2H-1-benzopyran-2-carboxylic acid, ethyl ester; 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1- benzopyran-2-propanoic acid; 7-[3~(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-2-methyl-8- propyl-2H-1-benzopyran-2-propanoic acid; 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-2-methyl-8- propyl-2H-1-benzopyran-2-propanoic acid, methyl ester; 7-[3-(4-acetyl-2-(cyclopropylmethyl)-3-methoxyphenoxy) propoxy]-3,4dihydro- 8-propyl-2H-1-benzopyran-2-carboxylic acid;
4 : WO 00/12086 PCT/US99/19062 . 0 d . “ 7-[[5-(4-acetyl-3-methoxy-2-propylphenoxy)pentyl]oxy]-3,4-dihydro-8-propyl- 2H-1-benzopyran-2-carboxylic acid; 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3, 4-dihydro-2H- 1-benzopyran-2-carboxylic acid; and 7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-benzoyl-3, 4-dihydro- 2H-1-benzopyran-2-carboxylic acid.
Preparation of Compounds Useful in this Invention
These compounds are prepared by processes set forth in U.S. Patent 4,889,871 issued December 26, 1989 to Djuric, et al. and U.S. Patent 4,788,214 issued
November 29, 1988 to Cohen et al. These patents are incorporated herein by reference in their entirety. The compounds useful in this invention are prepared by methods that result in the racemic compound or by stereospecific methods that result in the individual stereoisomers.
U.S. Pat. No. 4,665,203 issued May 12, 1987 discloses methods for making some " 15 of the intermediates used in making compounds of the present invention. The patent is incorporated herein by reference.
Preferred compounds useful in this invention, where R? is methyl or ethyl, are . generally prepared by alkylating the prior art phenol hydroxy (R? is H) compounds to form compounds of Formula (I) by conventional techniques. Thus, the reaction of the phenol hydroxy (R* is H) with methyl iodide in potassium carbonate provides the ether.
Dimethyl sulfate in acetone and base is also useful in preparing ethers. Alternatively, intermediates can be alkylated prior to forming the -O-(CH,)«-O- bridge. Hydrolysis of the ester compounds in the presence of lithium hydroxide and methanol gives the acid compounds.
The compounds of Formula (I) and those of U.S. Patent 4,788,214 that contain an asymmetric carbon atom at position 2 of the benzopyran ring are normally obtained from the synthesis as racemic mixtures. Resolution of the racemates into the corresponding optically active isomers (enantiomers) can be carried out by persons skilled in the art : using known procedures.
Compounds of Formula (I) when R’ is hydrogen are carboxylic acids. A racemic mixture of a carboxylic acid may be resolved by first treating the racemate with an optically active amine base to form a mixture of diastereomeric salts. Examples of optically active amine bases that may be used for this purpose are (R)-(+)-oc- methylbenzylamine, (S)-(-)- oc-methylbenzylamine, (1R,25)-(-)-ephedrine, quinine, and quinidine. The thusly formed diastereomeric salts have different properties, such as solubility, and the diastereomers may therefore be separated by selective recrystallization from a suitable solvent. The optically active carboxylic acids may then be obtained by re-acidification of the separated diastereomeric salts.
Alternatively, a racemic mixture of a carboxylic acid may be treated with an optically active alcohol to form a mixture of diastereomeric esters. Examples of optically active alcohols that may be used for this purpose are (1R,2S,5R)-(-)-menthol, (1S,2R,5S)- (+)- menthol, (R)-(-)-2-octanol, and (S)-(+)-2-octanol. The thusly-formed mixture of diastereomeric esters may then be separated by chromatography. The optically active carboxylic acids may then be obtained from the separated diastereomeric esters by conventional techniques, such as treatment of the esters with sodium hydroxide or lithium hydroxide followed by reacidification.
Compounds of Formula (I) when R’ is alkyl are esters. A racemate of the esters may be resolved into the enantiomers by first resolving a racemic mixture of the corresponding carboxylic acid using one of the methods described above. The optically active ester may be obtained by esterification of the corresponding optically active carboxylic acid by procedures similar to those used to prepare a racemic ester.
Alternatively, a racemic mixture of a carboxylic acid of Formula (I) or a racemic mixture of an ester of Formula (I), may be separated into the individual enantiomers by high performance liquid chromatography using a suitable chiral stationary phase and a suitable eluent.
h 4 ~~ WO00/12086 PCT/US99/19062
N Administration of Compounds Useful in this Invention : An aspect of this invention is a method of mitigating an adverse pharmacological effect of IL-2 in a subject at risk of, or in fact exhibiting, such effect. The method comprises administering to a subject receiving IL-2 an amount of a leukotriene receptor antagonist that is sufficient to mitigate the adverse effects of the IL-2. Generally the excess IL-2 is a result of IL-2 (e.g, PROLEUKIN®) administration to treat a malignancy, acquired immunodeficiency syndrome (AIDS) or other malady.
To mitigate the adverse effects induced by IL-2 administration, a compound is delivered at a level sufficient to reduce those effects. That amount will vary somewhat from subject to subject but generally will be in the range of about 0.1 mg to about 10.0 mg per kilogram of body weight per day. The preferred range is from 0.1 to 5.0 mg/kg/day while the most preferred range is from 1.0 to 5.0 mg/kg/day. Thus, for a 50 kg person, about 5.0 to 500 mg/day would be administered. For a 70 kg person about 7.0 to 700 mg/day.
In general, the adverse pharmacological effect of IL-2 in a subject will occur no | during the treatment of the subject for an IL-2-responsive disease state. Thus, the method, along with other aspects of the invention, is useful in treating a subject having a ’ leukotriene receptor in its system. This generally includes mammals, such as livestock and pets, and particularly humans. Thus, this invention will find use in treating humans of all ages as well as in treating animals, i.e., in veterinary uses. The invention may be ‘used for treating livestock such as cattle, sheep, pigs, goats, and the like or for treating household pets such as dogs, cats, rabbits, hamsters, mice, rats, and the like. The primary utility is for treating humans. IL-2 is administered to a human as part of the treatment of a malignant tumor, i.e., cancer, or a viral disease such as AIDS. The adverse : 25 pharmacological effect often seen in such treatment is increased vascular permeability, eg, VLS. The signs and symptoms of the adverse pharmacological effect are, for example, cardiovascular (hypotension requiring pressors; arrhythmias, pericardial effusion); pulmonary (congestion, dyspnea, pulmonary edema); hepatic (increased bilirubin, jaundice, ascites); hematologic (anemia, thrombocytopenia, leukopenia);
gastrointestinal (nausea, emesis, diarrhea, gastrointestinal bleeding); renal . (oliguria/anuria, decreased excretory function); dermatologic (pruritus, erythema, rash); musculoskeletal (arthralgia, myalgia); general (fever, pain, fatigue, weakness, edema, infection, weight gain, headache).
Thus, another aspect of this invention is a method of treating a malignancy or viral disease in a mammal, which method comprises administering a therapeutically effective amount of IL-2 in conjunction with the LA, as described herein, in an amount sufficient to mitigate IL-2-induced adverse physiological effects. The method may be performed by administering the IL-2 and the LA in combination as a unit dosage or the
IL-2 and the LA may be administered individually, with the LA being administered before, during or after the administration of the IL-2. The LA may be administered orally before, during or after the IL-2 is administered.
Viewed another way, this invention may be seen as an improvement in a method of treating a malignancy, or other malady requiring IL-2 treatment. The subject method comprises administering a therapeutically effective amount of IL-2. Because this treatment induces adverse pharmacological effects in the mammal, the improvement of this invention comprises administering the LA in an amount sufficient to mitigate IL-2 induced adverse pharmacological effects. ]
Human recombinant interleukin-2 is a well-studied, well-characterized and effective antineoplastic drug with well documented, often severe, and sometimes life- threatening or fatal side effects. One of the most serious is VLS, which can affect the entire body, but is often most serious when affecting the lungs.
According to the “package insert” provided by Chiron Therapeutics, IL-2 (PROLEUKIN®) is a highly purified protein with a molecular weight of approximately 15,300 Daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2. IL- 2, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analogue of the human interleukin-2 gene.
Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant
¥ woouzoss | PCT/US99/19062 . form differs from the native interleukin-2 in the follow ways: a) IL-2 is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125; this was accomplished by site specific manipulation during the genetic engineering procedure; and d) the aggregation state of PROLEUKIN® is likely to be different from that of native interleukin-2.
In addition, Chiron Therapeutics indicates that certain in vitro studies were performed to determine the properties of PROLEUKIN® and that these include: a) g 10 enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human : interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) . induction of Killer cell (lymphokine-activated [LAK] and natural [NK] activity; and d) induction of interferon-gamma production. In in vivo studies, IL-2 produces multiple immunological effects in murine models in a dose-dependent manner. These include: a) activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia; b) the production of other cytokines such as tumor necrosis factor, “ interleukin-1, and gamma interferon; c¢) inhibition of tumor growth. In addition, as noted previously, interleukin-2 has now been shown to stimulate the production of potentially . toxic and inflammatory leukotrienes. Despite the large amount of knowledge concerning the effects of IL-2, the exact mechanism by which IL-2 mediates its antitumor (and toxic) effects in humans is unknown.
A compound useful in this invention is administered to an appropriate subject in need of these compounds by a medically acceptable route of administration such as orally, parenterally (e.g, intramuscularly, intravenously, subcutaneously, interperitoneally), transdermally, rectally, by inhalation and the like.
Unit doses or multiple dose forms are contemplated, each offering advantages in certain clinical settings. The unit dose would contain a predetermined quantity of active compound calculated to produce the desired effect(s) in the setting of IL-2 coadministration. The multiple dose form may be particularly useful when multiples of single doses, or fractional doses, are required to achieve the desired ends. Either of these . dosing forms may have specifications that are dictated by or directly dependent upon the unique characteristic of the particular compound, the particular therapeutic effect to be achieved (e.g., the attenuation of IL-2 toxicity, especially VLS), and any limitations inherent in the art of preparing the particular compound for treatment of IL-2 toxicity or
VLS in living subjects.
A unit dose will contain an amount sufficient to mitigate the adverse effects induced by excess IL-2 in a subject and may contain from about 5.0 to 1000 mg of compound with the preferred range being 50 to 350 mg. The multiple dose form could contain from 0.2 to 4,000 mg with the preferred range being 100 to 500 mg.
The compound will preferably be administered orally in a suitable formulation as an ingestible tablet, a buccal tablet, capsule, caplet, elixir, suspension, syrup, trouche, wafer, lozenge, and the like. Generally, the most straightforward formulation is a tablet or capsule (individually or collectively designated as an “oral dosage unit”). Suitable formulations are prepared in accordance with a standard formulating techniques available that match the characteristics of the compound to the excipients available for formulating an appropriate composition. A tablet or capsule will contain about 25 to about 500mg of a compound of Formula (I), preferably about 50-250mg, and most preferably about 100- 200mg.
The form may deliver the LA rapidly or may be a sustained-release preparation.
The LA may be enclosed in a hard or soft capsule, may be compressed into tablets, or may be incorporated with beverages, food or otherwise into the diet. The percentage of the final composition and the preparations may, of course, be varied and may conveniently range between 1 and 70% of the weight of the final form, e.g., tablet. The amount of LA in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions according to the current invention are prepared so that an oral dosage unit form contains between about 2.5 to about 50 LA by weight (%w) in dosage units weighing between 50 and 1000 mg.
of i WO 00/12086 PCT/US99/19062 : The suitable formulation of an oral dosage unit may also contain: a binder, such as gum tragacanth, acacia, corn starch, gelatin; sweetening agents such as lactose or sucrose; disintegrating agents such as corn starch, alginic acid and the like; a lubricant such as magnesium stearate; or flavoring such a peppermint, oil of wintergreen or the like. Various other material may be present as coating or to otherwise modify the physical form of the oral dosage unit. The oral dosage unit may be coated with shellac, a sugar or both. Syrup or elixir may contain the LA, sucrose as a sweetening agent, methyl and propylparabens as a preservative, a dye and flavoring. Any material utilized should be pharmaceutically-acceptable and substantially non-toxic. Details of the types of excipients useful may be found in the nineteenth edition of “Remington: The Science and Practice of Pharmacy,” Mack Printing Company, Easton, PA. See particularly chapters 91-93 for a fuller discussion.
A compound may be administered parenterally, e.g., intravenously, intramuscularly, intravenously, subcutaneously, or interperitonieally. The carrier or excipient or excipient mixture can be a solvent or a dispersive medium containing, for example, various polar or non-polar solvents, suitable mixtures thereof, or oils. As used : herein “carrier” or “excipient” means a pharmaceutically acceptable carrier or excipient and includes any and all solvents, dispersive agents or media, coating(s), antimicrobial : agents, iso/hypo/hypertonic agents, absorption-modifying agents, and the like. The use of such substances and the agents for pharmaceutically active substances is well known in the art. Except in so far as any conventional media or agent is incompatible with the active ingredient, use in therapeutic compositions is contemplated. Moreover, other or supplementary active ingredients can also be incorporated into the final composition.
Solutions of the inhibitor may be prepared in suitable diluents such as water, ethanol, glycerol, liquid polyethylene glycol(s), various oils, and/or mixtures thereof, and others known to those skilled in the art.
The pharmaceutical forms suitable for injectable use include sterile solutions, dispersions, emulsions, and sterile powders. The final form must be stable under conditions of manufacture and storage. Furthermore, the final pharmaceutical form must be protected against contamination and must, therefore, be able to inhibit the growth of : microorganisms such as bacteria or fungi. A single intravenous or intraperitoneal dose can be administered. Alternatively, a slow long term infusion or multiple short term daily infusions may be utilized, typically lasting from 1 to 8 days. Alternate day or dosing once every several days may also be utilized.
Sterile, injectable solutions are prepared by incorporating a compound in the required amount into one or more appropriate solvents to which other ingredients, listed above or known to those skilled in the art, may be added as required. Sterile injectable solutions are prepared by incorporating the compound in the required amount in the appropriate solvent with various other ingredients as required. Sterilizing procedures, such as filtration, then follow. Typically, dispersions are made by incorporating the compound into a sterile vehicle which also contains the dispersion medium and the required other ingredients as indicated above. In the case of a sterile powder, the preferred methods include vacuum drying or freeze drying to which any required ingredients are added.
In all cases the final form, as noted, must be sterile and must also be able to pass ) readily through an injection device such as a hollow needle. The proper viscosity may be achieved and maintained by the proper choice of solvents or excipients. Moreover, the } use of molecular or particulate coatings such as lecithin, the proper selection of particle size in dispersions, or the use of materials with surfactant properties may be utilized.
Prevention or inhibition of growth of microorganisms may be achieved through the addition of one or more antimicrobial agents such as chlorobutanol, ascorbic acid, parabens, thermerosal, or the like. It may also be preferable to include agents that alter the tonicity such as sugars or salts.
Another aspect of this invention is an article of manufacture that comprises a pharmaceutical composition comprising a leukotriene receptor antagonist (as described herein) as a unit dosage in combination with printed labeling instructions for administering the composition to a mammal undergoing treatment of a malignancy or of © WO 00/12086 | PCT/US99/19062 : viral disease with IL-2, wherein the amount of the composition administered is sufficient to reduce IL-induced adverse pharmacological effects in the mammal being treated.
An advantage of this invention is that it obviates the need to place patients into intensive care units and onto respirators in the case of severe pulmonary edema, or to place patients into cardiac or coronary care units in the case of severe arrhythmias or congestive heart failure or onto dialysis protocols in the case of renal compromise. A further advantage is the reduction of intensive nursing care or supportive care or need of
ICUs or CCUs. } Moreover, the mitigation of IL-2-related adverse events enables the safe administration of higher doses of IL-2 such that the antitumor efficacy of the combined regimen (LA+IL-2) is superior to IL-2 alone.
A compound of particular value in this invention is (+)7-[3-(4-acetyl-3-methoxy- i 2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid:
The compound is a potent, highly selective leukotriene B4 receptor antagonist. A summary of its properties appears below. i In Vitro Pharmacology
Inhibition of LTB4 binding to human neutrophils
IC50 = 0.3 micromolar
Inhibition of LTB4 chemotaxis | oo range = 0.3 - 3.0 micromolar
Inhibition of human neutrophil adhesion to LTB4-stimulated umbilical vein endothelial cells © range = 0.3 - 1.0 micromolar
Inhibition of LTB4-induced neutrophil granulation range = 1 — 3 micromolar .
Inhibition of LTB4 synthesis
IC50 = 2.1 micromolar
Inhibition of LTA4 conversion into LTB4
IC50=20 micromolar
In Vivo Pharmacology
Inhibition of LTB4 chemotaxis in guinea pigs
ED50 = 0.6 mg/kg 1.8.
Inhibition of 12 (R) - HETE in guinea pigs
EDS50=20mg/kgli.g.
Inhibition of acetic acid colonic inflammation in rats and guinea pig
ED50 = 20 mg/kg i.g. .
Inhibition of calcium ionophore dermal inflammation in the guinea pig ear
ED50 = 0.7 mg/ear
These in vitro and in vivo data establish the potency and selectivity of the preferred compound and are particularly relevant to diminishing, i.e., mitigating the unwanted effects of IL-2. These data are also particularly relevant to establishing that leukotriene B4 mediated responses, including VLS, whether induced initially by administration of IL-2 or by other means, are blunted by the preferred compound.
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
h WO 00/12086 . PCT/US99/19062 : The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
Example 1
This example is a reproduction (without formulae) of Example 1 from U.S. Patent 4,889,871 and sets forth a method for making a preferred compound useful in this invention, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl- 2H-1-benzopyran-2-carboxylic acid. (a) 493 mg of methyl 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]- 3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylate was added to 25 ml of acetone containing 276 mg of anhydrous potassium carbonate and 282 mg of methyl iodide. The mixture was refluxed for about 24 hours and water was added and the mixture was then extracted with ethyl acetate. The extract was dried, the solvent removed under vacuum, and the residual oil was chromatographed over silica gel with a 40/60 mixture of ethyl acetate/hexane to provide pure-methyl ether, methyl 7-[3[(4-acetyl-3-methoxy-2- ’ propylphenoxy)propoxy]-3,4-dihydro-8- propy-2H-1-benzopyran-2-carboxylate. . + (b) The methyl ether (340 mg) was dissolved in methanol (5 ml) containing lithium hydroxide (0.7 ml of a 2N LiOH solution in water). The mixture was stirred at room temperature overnight and the solvent removed in vacuo. The residue was partitioned between ethyl acetate and 2N HC1 and the organic layer separated and washed with brine. Evaporation of the volatiles in vacuo afforded crude acid. This material was purified by silica gel chromatography using ethyl acetate/hexane/acetic acid (40:60:0.5) as eluant. The pure product was recrystallized from ethyl acetate/hexane to afford 200 mg of product, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]- 3,4- dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid, m.p. 65°-68° C.
Microanalysis: Found: C 69.22, H 7.53. Theory: C 69.40, H 7.49.
The NMR (CDCI;) shows a -OCH3 at 83.75.
Example 2
This example explains how compound of Formula (I) is administered to sheep to mitigate the adverse effect of excess IL-2.
Preparation of Sheep
Yearling male or female interbred sheep (N A 24) and weighing approximately 20 to 40 kg are prepared with chronic lung lymph fistulae essentially according to a modification of the technique described by Staub et al (see “Relevant Literature,” supra at 6 and as further described within reference 2 herein and other references cited within reference 2). Through a thoracotomy, the efferent duct of the caudal mediastinal lymph node is cannulated, the distal portion of the lymph node below the level of the inferior pulmonary ligament is ligated, and the diaphragm around the lymph node is circumferentially cauterized or otherwise securely closed. All visible systemic lymph tributaries to the proximal portion are cauterized or ligated to minimize extra-pulmonary contamination of collected lymph. A suitable thermistor-tipped pulmonary arterial and central venous catheter are introduced through the right internal jugular vein. The aorta is then cannulated via the adjacent carotid artery. After a recovery period of a variable number of days, preferably 4-5, when the animals appear vigorous again, are afebrile, and have a steady flow of blood-free lymph, the experiment is conducted.
EF] . WO 00/12086 PCT/US99/19062 . Measurement of Cardiopulmonary Function : To measure cardiopulmonary function, suitable strain-gauge transducers are used to measure the following pressures: mean arterial pressure (MAP); mean pulmonary wedge pressure (MPAP, and the pulmonary arterial wedge pressure (PAWP). The pulmonary microvascular pressure (Pmv) is calculated from the Gaar equation where : Pmv = PAWP + 04 ¥ (MPAP-PAWP). Pulse rate is determined from the arterial pressure tracings. Cardiac output is measured serially by thermodilution or dye techniques using suitable, standard equipment. Arterial blood gases, pH, oxygen saturation, and hemoglobin levels are also measured with suitable, standard laboratory equipment and by spectrophotometry using extinction coefficients determined for the species being tested.
Hematology
Circulating platelets and leukocytes are counted by means of standard laboratory equipment or by phase microscopy while leukocyte differential counts are determined by counting microscopically on ruled stages of Wrights stained blood smears.
Biochemical Assays ) Concentrations of leukotrienes and thromboxanes are measured using standard radioimmunoassays. Such measurements are or can be made on lung lymph as well. In addition, lymphatic (LY) and plasma (PL) total protein concentrations are determined by using standard spectrophotometric techniques. The LY/PL protein ratio is calculated and multiplied by lymph flow (QL) to obtain the lymphatic protein clearance rate.
IL-2
The recombinant interleukin-2 (PROLEUKIN®) is utilized. The dose of IL-2 can be varied as desired. The preferred range is 1,000 to 1,000,000 IU/kg while the most preferred range is 400,000 to 800,000 IU/kg.
Protocol
Experiments are or can be performed on conscious, instrumented sheep having free access to food and water. Sheep are allowed to stand or recline as desired.
Transducers are re-leveled as necessary to accommodate the sheep stance or posture.
Baseline measurements are obtained for variable lengths of time with the preferred period being at least one hour.
Certain animals receive IL-2 alone, 400,000 to 800,000 IU/kg, given either as a bolus injection over one to several minutes or as a slower infusion over several minutes to several hours. Other animals receive the same IL-2 treatment but also receive, for example, the compound. The compound may be given by any of the routes identified previously. For simplicity in the animal laboratory, intravenous dosing is preferred although oral dosing is also acceptable. Effective doses of the LA range from 0.1 mg/kg/day to 10 mg/kg/day, while the preferred dose range is 0.1 to 2.0 mg/kg/day and the most preferred dose range is 0.5 to 1.0 mg/kg/day. When given intravenously, the LA may be dosed either as a bolus injection over one to several minutes or as a slower infusion over several minutes to several hours. Maintaining continuous but not necessarily invariant levels of LA during IL-2 exposure is preferred but is not necessary.
LA dosing may begin before, during, or after the IL-2 administration. It is preferred to begin LA before IL-2 administration and is most preferred to begin dosing at least one hour prior to the start of IL-2 administration. The purpose of this prophylactic regimen is to establish effective blockade of the leukotriene receptors prior to IL-2- induced increases in plasma levels of leukotrienes.
Cardiopulmonary function, lymph flows and protein content, hematology and other chemical laboratory tests are assessed during and for several hours after IL-2 administration begins. In this model it is preferred to monitor animals as described for a period of 4-6 hours.
Results y WO 00/12086 PCT/US99/19062 : The in vitro and in vivo results demonstrate the effectiveness of the referenced compound in mitigating, reducing or eliminating leukotriene B4 induced biological responses. Appropriate analysis of the data from the ovine experiment described herein extend the beneficial effects of LA’s, LA’s preferably, and the referenced LA most preferably, to the setting of preventing IL-2-induced VLS and adverse alterations in cardiopulmonary function and laboratory testing.
Example 3 . This example explains how a compound of Formula (I) is administered to rats to mitigate the adverse effect of excess IL-2 in rats.
Test Material
A preferred LA compound, (+) 7 — [3-(4-acetyl-3-methoxy-2-propylphenoxy) propoxy]-3, 4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid, (Lot Number 101- 8802) was supplied as a white crystalline solid by BioMedicines, Inc. For intraperitoneal (i.p.) injection, the LA was freshly dissolved in a mixture of 0.1 M potassium phosphate
SE 15 buffer (pH 6.8), ethanol, and propylene glycol (65:20:15 by volume). The concentration of the LA solution was adjusted so that the volume for each injection was 3 ml/kg for all : groups.
IL-2
Proleukin® for Injection (Chiron Therapeutics) recombinant human interleukin-2 (IL-2), is supplied as a lyophilized powder in vials containing 22 million international units (MIU). For intravenous (i.v.) injection, Proleukin was reconstituted with Sterile
Water for Injection, USP, to provide a solution of 18 million IU/ml. The reconstituted solution was further diluted with 5% Dextrose Injection, USP as needed so that the volume for each injection was 0.208 ml/rat. The dose can be varied as usual. The preferred range for purposes of this example is 6 — 24 MIU/kg while the most preferred range is 10-15 MIU/kg. Any of the previously mentioned routes of administration may be used. The preferred route is i.v. or intraperitoneal (i.p.) while the most preferred, for purposes of this example, is i.v.
Animals i
Male Sprague Dawley rats were obtained from Harlan Sprague Dawley, Inc.,
Indianapolis, Indiana. All rats were six to eight weeks old and weighed approximately 250 to 300 g when used in the experiments. Each animal was numbered on the tail with indelible ink. The animals were housed in groups of up to three per cage and were allowed access to standard chow and water ad libitum. The study was conducted at an
AAALAC accredited facility in compliance with the National Institutes of Health “Guide for the Care and Use of Laboratory Animals,” Publication No. 86-23 and the USDA
Laboratory Animal Welfare Act, Publication L. 89-544.
Experimental Protocol
Six groups of animals were studied (total N = 57) in a modification of the technique of Edwards et al (Edwards MJ, Miller FN, Simms DE et al. Interleukin-2
Acutely Induces Platelet and neutrophil-Endothelial Adherence and Macromolecular
Leakage. Cancer Research 52: 1992:3425-31). Animals were weighed on the day of dosing and the appropriate doses of IL-2 and/or LA were calculated. The animals remained conscious throughout the experiment until an anesthetic was administered ) approximately 10 minutes before exsanguination. The anesthetic consisted of a mixture of ketamine (45 mg/ml) xylazine (2.5 mg/ml), and acepromazine (0.37 mg/ml) diluted with water and administered subcutaneously at a dose of 2.0 ml/kg.
Group 1 (n=14) consisted of control animals that received both iv. and i.p. injections of vehicle. The other five groups received i.v. injections of IL-2 via the tail vein. Groups 2 (n = 8), 3 (n = 4), and 4 (n = 10) received IL-2 in doses of 1.5, 6.0, and 12.5 million TUMIU)/kg, respectively. In addition to 12.5 million IU/kg of IL-2, Groups 5 (n= 8) and 6 (n = 13) received i.p. injections of the LA. The LA was administered in two equal, divided doses; the first dose of LA was given 20 minutes before administration of IL-2 and the second dose was given 50 minutes after administration of
IL-2. Group 5 was administered 2 x 10 mg/kg of the LA. Group 6 was administered 2 x mg/kg of the LA.
<q WO 00/12086 PCT/US99/19062 (5 . / J : Two hours after the IL-2 injection, the animals were exsanguinated via the abdominal aorta and the arterial blood was collected for measurement of PaO2.
Measurement of Blood Oxygen Levels
Whole arterial blood was collected into heparinized blood arterial gas syringes.
Immediately after collection, the blood sample was analyzed using PaO2 electrode model
DO-166FT. Sample blood was pre-oxygenated and used as a standard before and after each test sample.
Analysis of Data
Data are shown as mean + SEM. Data were analyzed using the Tukey-Kramer test (JMP® statistical software from SAS, Inc.) Significance was defined as a p-value less than 0.05.
Results of In vivo Study ; Progressively higher doses of interleukin-2 progressively reduced arterial oxygen : . levels in the rodent. With a dose of 12.5 MIU IL-2, oxygen levels in the rat declined . 15 from a control value of 93.0+2.2 mm Hg to 77.5 + 2.5 mm Hg (p<0.001). When LA was : . administered as described the reduction in oxygenation induced by IL-2 was mitigated (p>.0.5 vs control and p< 0.001 vs IL-2 alone for both LA-treated groups; see Figure 1).
R % WO 00/12086 PCT/US99/19062 :
Discussion : Interleukin-2 predictably lowers arterial oxygenation in humans when administered in a sufficiently high dose. This is an adverse pharmacological effect. This reduction in oxygenation is attributable to impaired ventilatory responses that occur, at least in part, because of the VLS induced by IL-2. The current in vitro findings demonstrate that the LA utilized in this example blocks leukotriene B4 receptors and thereby reduces leukotriene B4 activity. Furthermore, the in vivo findings demonstrate that the administration of an LA prevents the clinically important adverse event of hypoxemia associated with exposure to IL-2 and thereby demonstrating a beneficial effect in preventing the VLS caused by IL-2.
The unit “mmHg” which is used in the specification and which is not in accordance with the metric system may be converted with the aid of the following conversion factor:
To convert from To Multiply by mmHg Pascal (Pa) 133,322 26.
Amended Sheet 22/01/2002
Claims (24)
1. The use of a leukotriene receptor antagonist in an amount sufficient to mitigate an adverse pharmacological effect of IL-2 in the manufacture of a medicament for use in a method of mitigating such an adverse effect in a subject at risk of, or in fact exhibiting, such adverse effect.
2. The use of Claim 1 wherein IL-2 is administered to a human as part of the treatment of a malignancy or a viral disease.
3. The use of Claim 1 wherein the adverse pharmacological effect is increased vascular permeability. :
4. The use of Claim 3 wherein the signs and symptoms of the adverse pharmacological effect include edema, systemic hypotension, reduced organ perfusion, or dysfunction of one or more organs, tissues or cells of the subject body.
5. The use of Claim 1 wherein the leukotriene receptor antagonist is represented by the formula
@
. Rr? I R ’ 1 R37 ¢ R R RS Ne 0 A : 0—wW-—0 RE NN H or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein R' represents hydrogen, alkyl having 2 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, or (CH;).R wherein R represents cycloalkyl of 3 to 5 carbon atoms and n 1s 1 or 2;
27. : Amended Sheet 22/01/2002 bh WO 00/12086 PCT/US99/19062 . R? represents hydrogen, methyl or ethyl; : : : rR? represents alkyl having 1 to 5 carbon atoms; W represents (CH,)x where x 1s 2 to 7, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms or cyclopentylene; : 5 R* represents hydrogen, alkyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkanoyl of 2 to S carbon atoms or aralkanoyl of 7 to 9 carbon atoms; : rR? represents hydrogen, alkyl having 1 to 6 carbon atoms, or R? represents . alkanoyl having 2 to 4 carbon atoms, or (CHy)y - CO,R® wherein Y is 0 to 4 and Ris hydrogen or alkyl having 1 to 6 carbon atoms; RS represents hydrogen or together with R® represents a carbon to carbon bond; and A represents - Z - CO,R’ wherein R’ represents hydrogen or alkyl having 1 to 6 carbon atoms, and wherein Z is absent or represents straight or branched chain alkylene : or alkenylene having up to 6 carbon atoms.
6. The use of Claim 5 wherein the leukotriene receptor antagonist is represented by Formula (I) and -R! represents alkyl having 2 to 4 carbon atoms; : R? represents hydrogen, methyl or ethyl; rR? represents alkyl having 1 to 3 carbon atoms; W represents (CH,)x where x is 3 to 5, alkenylene having 3 to 5 carbon atoms, alkynylene having 3 to 5 carbon atoms, or cyclopentylene; R* represents alkyl having 2 to 4 carbon atoms, acetyl or benzoyl; R? represents hydrogen or alkyl having 1 to 4 carbon atoms; : 28." Amended Sheet 22/01/2002
COR WO 00/12086 PCT/US99/19062 R® represents hydrogen; and : A represents - Z - CO,R’, wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms, and wherein Z is absent or represents alkylene having up to 2 carbon atoms.
7. The use of Claim 6 wherein the leukotriene receptor antagonist is represented by Formula (I) and R! is n-propyl; R? and R® each is methyl; oo W is (CHa)x, where x 1s 3,4 or 5; R* is 8-n-propyl; R’ represents hydrogen or alkyl of 1 to 4 carbon atoms; and A represents - Z - CO,R” wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms and Z is absent or represents alkylene having up to 2 carbon atoms. oo
8. The use of Claim 7 wherein the leukotriene receptor antagonist is represented by Formula (I) and W is (CHa)s, R® is H and A is (CH), - COOH where p is 0,1 or 2.
9. The use of Claim 8 wherein the leukotriene antagonist is represented by Formula (I) and A is -COH.
10. The use of Claim 6 wherein R' is n-propyl, R? is hydrogen, R’ is methyl, Wis (CHy)s, R* is 6-acetyl, R® is hydrogen, and A is COOH.
11. The use of a therapeutically effective amount of IL-2 in conjunction with a leukotriene receptor antagonist in an amount sufficient to reduce IL-2-induced adverse pharmacological effects in the manufacture of a medicament for use in a method of treating a malignanacy or a viral disease in a subject.
29. Amended Sheet 22/01/2002
N WO 00/12086 PCT/US99/19062 .
12. The use of Claim 11 wherein the adverse pharmacological effect is increased vascular permeability.
13. The use of Claim 12, wherein the signs and symptoms of the adverse . pharmacological effect include one or more of edema, systemic hypotension, reduced organ perfusion, or dysfunction of one or more organs, tissues or cells of the subject’s body.
14. The use of Claim 11, wherein the leukotriene receptor antagonist is represented by the formula : @ RZ po 1 : . re —C R R* RS New OA NN H } or a stereoisomer or a pharmaceutically acceptable salt thereof wherein R' represents alkyl having 2 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, or (CH;),R wherein R represents cycloalkyl of 3 to 5 carbon atoms and nis 1 or 2; : R? represents hydrogen, methyl or ethyl; R’ represents alkyl having 1 to 5 carbon atoms; W represents (CH;), where x is 2 to 7, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7, or cyclopentylene; : R* represents hydrogen, alkyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkanoyl of 2 to 5 carbon atoms, or aralkanoy! of 7-9 carbon atoms;
30. Amended Sheet 22/01/2002
TN WO 00/12086 PCT/US99/19062 R® represents hydrogen, alkyl having 1 to 6 carbon atoms, or R® represents alkanoyl having 2 to 4 carbon atoms, or (CHy)y - CO*R® wherein y is 0 to 4 and R® is hydrogen or alkyl having 1 to 6 carbon atoms; RS represents hydrogen or together with R® represents a carbon to carbon bond, and A represents - Z - CO,R’ wherein R’ represents hydrogen or alkyl having 1 to 6 : carbon atoms, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms.
15. The use of Claim 14 wherein the leukotriene receptor antagonist 1s : represented by Formula (I) and R! represents alkyl having 2 to 4 carbon atoms; R? represents hydrogen, methyl or ethyl; rR’ represents alkyl having 1 to 3 carbon atoms; W represents (CHa) where x is 3 to 5, alkenylene having 3 to 5 carbon atoms, oo 15 alkynylene having 3 to 5 carbon atoms, or cyclopentylene; R* represents alkyl having 2 to 4 carbon atoms, acetyl or benzoyl; R’ represents hydrogen or alkyl having 1 to 4 carbon atoms; R® represents hydrogen; and A represents -Z-CO,R’, wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms, and wherein Z is absent or represents alkylene having up to 2 carbon "atoms.
16. The use of Claim 15 wherein the leukotriene receptor antagonist 1s represented by Formula (I) and R'is n-propyl;
31. Emended Sheet 22/01/2002
R? and R? each is methyl; : W 1s (CH,),, where x is 3,4 or 5; Rs is 8-n-propyl; Rs represents hydrogen or alkyl of 1 to 4 carbon atoms; and A represents ~Z-CO,R’ wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms and Z is absent or represents alkylene having up to 2 carbon atoms.
17. The use of Claim 16 wherein the leukotriene receptor antagonist is represented by Formula (I) and W is (CHy)s, R’isH and A is (CHy), - COOH where p is 0,1 or 2.
18. The use of Claim 17 wherein the leukotriene antagonist is represented by Formula (T) and A is -COOH.
19. The use of Claim 15 wherein R' is n-propyl, R? is hydrogen, R® is methyl, W is (CHa)s, R" is 6-acetyl, R’ is hydrogen, and A is COOH.
20. The use . of Claim 11 wherein.the IL-2 and the leukotriene receptor. So 15 antagonist are administered in combination as a unit dosage.
21. The use of Claim 11 wherein the IL-2 and the leukotriene receptor antagonist are administered individually. :
22. The use of Claim 21 wherein the leukotriene receptor antagonist is administered orally before, during or after the IL-2 is administered.
23. An article of manufacture that comprises a pharmaceutical composition comprising a leukotriene receptor antagonist as a unit or multiple dosage in combination with printed labeling instructions for administering the dosage to a subject undergoing treatment of a malignancy or viral disease with IL-2, wherein the amount of the composition administered is sufficient to mitigate IL-induced adverse pharmacological effects in the mammal being treated.
32. : Amended Sheet 22/01/2002
4” | WO 00/12086 PCT/US99/19062 6) :
24. The article of manufacture of Claim 23 wherein the adverse pharmacological effect is increased vascular permeability.
25. The article of manufacture of Claim 24 wherein the signs and symptoms of the adverse pharmacological effect include one or more of edema, systemic hypotension, reduced organ perfusion, or dysfunction of one or more organs of the mammal’s body.
26. The article of manufacture of Claim 23 wherein the leukotriene receptor antagonist is represented by the formula @ R? no 1 RS _C R rR? RS Ne 0 A 0O—W—0 R® NS H or a stereoisomer or a pharmaceutically acceptable salt thereof wherein R! represents alkyl having 2 to 6 carbon atoms, alkenyl having 2 to 6 carbon atoms, alkynyl having 2 to 6 carbon atoms, or (CH;),R wherein R represents cycloalkyl of3to5 carbon atoms and nis 1 or 2; R? represents hydrogen, methyl or ethyl; R? represents alkyl having 1 to 5 carbon atoms; W represents (CH), where x is 2 to 7, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms, or cyclopentyl;
§ R* represents hydrogen, alkyl having 2 to 5 carbon atoms, alkynyl having 2 to 5 carbon atoms, alkenyl having 2 to 5 carbon atoms, alkanoyl of 2 to 5 carbon atoms, or aralkanoyl of 7 to 9 carbon atoms; R> represents hydrogen, alkyl having 1 to 6 carbon atoms, or R® represents alkanoyl having 2 to 4 carbon atoms, or (CHy)y - CO,R® wherein Y is 0 to 4 and R® is hydrogen or alkyl having 1 to 6 carbon atoms; RS represents hydrogen or, together with R?, represents a carbon to carbon bond; andA represents - Z - COR’ wherein R’ represents hydrogen or alkyl having 1 to 6 carbon atoms, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms.
27. The article of manufacture of Claim 26 wherein the leukotriene receptor antagonist is represented by Formula (I) and : R! represents alkyl having 2 to 4 carbon atoms; R? represents hydro gen, methyl or ethyl; R? represents alkyl having 1 to 3 carbon atoms; W represents (CH,)x where x is 3 to 5, alkenylene having 3 to 5 carbon atoms, alkynylene having 3 to 5 carbon atoms, or cyclopentylene; .R* represents alkyl having 2 to 4 carbon atoms, acetyl or benzoyl; R’ represents hydrogen, alkyl having 1 to 4 carbon atoms; RS represents hydrogen; and A represents - Z - CO;R’, wherein R’ represents hydrogen or alkyl having 1 to 4 carbon atoms, and wherein Z is absent or represents alkylene having up to 2 carbon atoms. 34, : Amended Sheet 22/01/2002
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9834198P | 1998-08-28 | 1998-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200101048B true ZA200101048B (en) | 2002-02-07 |
Family
ID=27733485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200101048A ZA200101048B (en) | 1998-08-28 | 2001-02-07 | Method of mitigating the adverse effects of Interleukin-2. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200101048B (en) |
-
2001
- 2001-02-07 ZA ZA200101048A patent/ZA200101048B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100277621B1 (en) | New Pharmaceutical Compositions | |
KR100674122B1 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
KR100770695B1 (en) | Agonists specific for the peripheral cannabinoid receptor | |
KR100902799B1 (en) | Drugs containing chymase inhibitor and ace inhibitor as the active ingredients | |
EA009939B1 (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
US5906984A (en) | Methods of using aminothiols to promote hematopoietic progenitor cell growth | |
KR20140020840A (en) | Lipoyl compounds and their use for treating ischemic injury | |
JPH09501653A (en) | Pharmaceutical composition | |
EP1115397B1 (en) | Compositions for mitigating the adverse effects of interleukin-2 | |
GB2173500A (en) | Benz (b)indeno (2, 1-d)pyran drugs | |
US10344001B2 (en) | Azolylacryloyl derivatives as therapeutic agents for sickle cell disease | |
ZA200101048B (en) | Method of mitigating the adverse effects of Interleukin-2. | |
KR101441022B1 (en) | Medium-chain length fatty alcohols as stimulators of hematopoiesis | |
JPH0840893A (en) | Interleukin-1 production inhibitor | |
EP0579222B1 (en) | Lipid metabolism improving composition | |
US20040242676A1 (en) | Method of mitigating the adverse effects of IL-2 | |
US6479676B1 (en) | OxiranEcarboxylic acids for the treatment of diabetes | |
JP3130368B2 (en) | Liver function improving drugs | |
RU2782931C2 (en) | Indol-3-carboxic acid derivatives with anti-tumor activity | |
KR900000383A (en) | New compounds | |
JP2545279B2 (en) | Thrombocytopenia preventive and therapeutic agent | |
JP2023141229A (en) | Pharmaceutical composition used for treatment of hyperphosphatemia | |
JP2019142815A (en) | Heart failure improver | |
JP2009046403A (en) | Phenylpyrrole derivative and rage inhibitor | |
JPH07138226A (en) | New medicine for promotion of blood circulation |